Post-diagnosis statin use and survival among lung cancer patients in the Military Health System

IF 2.3 3区医学 Q3 ONCOLOGY

Cancer Epidemiology Pub Date : 2025-07-30 DOI:10.1016/j.canep.2025.102897

Jie Lin , Robert F. Browning Jr. , Craig D. Shriver , Kangmin Zhu

{"title":"Post-diagnosis statin use and survival among lung cancer patients in the Military Health System","authors":"Jie Lin , Robert F. Browning Jr. , Craig D. Shriver , Kangmin Zhu","doi":"10.1016/j.canep.2025.102897","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>There have been no studies examining the relationship between statin use and lung cancer survival in the U.S. Military Health System (MHS), a universal healthcare system. This study assessed whether statin use after lung cancer diagnosis is associated with overall survival among MHS beneficiaries with lung cancer.</div></div><div><h3>Methods</h3><div>This study was based on the Military Cancer Epidemiology (MilCanEpi) database, a database linking the DoD’s Central Cancer Registry (CCR) and the MHS Data Repository (MDR). The study subjects were MHS beneficiaries diagnosed with non-small cell lung cancer (NSCLC). Information on statin use was extracted from the database. Time-dependent Cox proportional hazard regression model was used to estimate hazard ratios (HRs) and 95 % confidence intervals (95 % CIs) comparing post-diagnosis use of statin relative to non-users.</div></div><div><h3>Results</h3><div>Among the 5096 patients, 864 patients used a statin after NSCLC diagnosis. Compared to individuals who never used statin, increased cumulative use of statin (per one-year of use) among the users conferred a significantly improved survival with an adjusted HR of 0.82 (95 % CI=0.75–0.90). In stratified analysis, the survival benefit or its tendency associated with increased cumulative use was observed regardless of age, race, sex, tumor stage, comorbidity index or baseline use.</div></div><div><h3>Conclusions</h3><div>Post-diagnosis statin use was associated with improved survival among NSCLC patients in a universal healthcare system.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"98 ","pages":"Article 102897"},"PeriodicalIF":2.3000,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Epidemiology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1877782125001572","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

There have been no studies examining the relationship between statin use and lung cancer survival in the U.S. Military Health System (MHS), a universal healthcare system. This study assessed whether statin use after lung cancer diagnosis is associated with overall survival among MHS beneficiaries with lung cancer.

Methods

This study was based on the Military Cancer Epidemiology (MilCanEpi) database, a database linking the DoD’s Central Cancer Registry (CCR) and the MHS Data Repository (MDR). The study subjects were MHS beneficiaries diagnosed with non-small cell lung cancer (NSCLC). Information on statin use was extracted from the database. Time-dependent Cox proportional hazard regression model was used to estimate hazard ratios (HRs) and 95 % confidence intervals (95 % CIs) comparing post-diagnosis use of statin relative to non-users.

Results

Among the 5096 patients, 864 patients used a statin after NSCLC diagnosis. Compared to individuals who never used statin, increased cumulative use of statin (per one-year of use) among the users conferred a significantly improved survival with an adjusted HR of 0.82 (95 % CI=0.75–0.90). In stratified analysis, the survival benefit or its tendency associated with increased cumulative use was observed regardless of age, race, sex, tumor stage, comorbidity index or baseline use.

Conclusions

Post-diagnosis statin use was associated with improved survival among NSCLC patients in a universal healthcare system.

查看原文本刊更多论文

军队卫生系统肺癌患者诊断后他汀类药物的使用与生存

背景：在美国军事卫生系统（MHS）中，还没有研究检查他汀类药物使用与肺癌生存率之间的关系。本研究评估肺癌诊断后他汀类药物的使用是否与MHS受益人肺癌患者的总生存率相关。方法本研究基于军事癌症流行病学（MilCanEpi）数据库，该数据库连接国防部中央癌症登记处（CCR）和MHS数据库（MDR）。研究对象是诊断为非小细胞肺癌（NSCLC）的MHS受益人。从数据库中提取他汀类药物使用的信息。使用时间相关的Cox比例风险回归模型来估计诊断后使用他汀类药物与未使用他汀类药物的风险比（hr）和95 %置信区间（95 % ci）。结果5096例患者中，864例患者在确诊为非小细胞肺癌后使用了他汀类药物。与从未使用过他汀类药物的患者相比，他汀类药物累计使用量（每使用一年）的增加显著提高了患者的生存率，调整后风险比为0.82（95 % CI= 0.75-0.90）。在分层分析中，无论年龄、种族、性别、肿瘤分期、合并症指数或基线使用情况如何，都观察到与累积使用增加相关的生存获益或其趋势。结论：在全民医疗保健系统中，诊断后使用他汀类药物可提高非小细胞肺癌患者的生存率。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Epidemiology 医学-肿瘤学

CiteScore

4.50

自引率

3.80%

发文量

200

审稿时长

39 days

期刊介绍： Cancer Epidemiology is dedicated to increasing understanding about cancer causes, prevention and control. The scope of the journal embraces all aspects of cancer epidemiology including: • Descriptive epidemiology • Studies of risk factors for disease initiation, development and prognosis • Screening and early detection • Prevention and control • Methodological issues The journal publishes original research articles (full length and short reports), systematic reviews and meta-analyses, editorials, commentaries and letters to the editor commenting on previously published research.